Zakharyants A A, Burmistrova O A, Poloznikov A A
BioClinicum Center, Moscow, Russia.
Bull Exp Biol Med. 2017 Feb;162(4):515-519. doi: 10.1007/s10517-017-3651-z. Epub 2017 Feb 27.
The possibility of interactions between warfarin and dasatinib and their interactions with other drugs metabolized by cytochrome P450 isoform CYP3A4 was demonstrated using a previously created cytochrome P450 substrate-inhibitor panel for preclinical in vitro studies of drug biotransformation on a 3D histotypical microfluidic cell model of human liver (liver-on-a-chip technology). Dasatinib and warfarin are inhibitors of CYP2C19 isoform and hence, can interfere the drugs metabolized by this isoform. Our findings are in line with the data obtained on primary culture of human hepatocytes and suggest that the model can be used in preclinical in vitro studies of drugs.
利用先前创建的细胞色素P450底物-抑制剂组合,在人肝脏的三维组织型微流控细胞模型(芯片上的肝脏技术)上进行药物生物转化的临床前体外研究,证明了华法林与达沙替尼之间相互作用的可能性,以及它们与其他由细胞色素P450同工酶CYP3A4代谢的药物之间的相互作用。达沙替尼和华法林是CYP2C19同工酶的抑制剂,因此,它们会干扰由该同工酶代谢的药物。我们的研究结果与在原代人肝细胞培养中获得的数据一致,并表明该模型可用于药物的临床前体外研究。